glp-1 drug market size Analogues Size, Share & Growth Drivers By 2034 GLP-1 Agonists Market Report 2025-2033,
Description
In rodents, the 1.3 kb 5-flanking sequence is sufficient to direct transgene expression to Gcg + cells in the brain and the pancreas [95] but extension of this region to include 2.5 kb is required to target Gcg + cells in the intestine [96], including evolutionarily preserved sequences in the first intron [97]
Ready for deeper support
2024;7(5):e2413172
What are the common side effects of GLP-1 therapies
In addition to the hormones GIP and glucagon, other hormones such as estrogen, peptide tyrosine tyrosine (PYY), gastrin, xenin, and fibroblast growth factor 21 can be good candidates to pair with GLP-1 and create dual agonists that have anti-diabetic and anti-obesity effects
Some evidence suggests dual agonists might better preserve lean body mass during weight loss, though this remains under investigation
